trending Market Intelligence /marketintelligence/en/news-insights/trending/Tj6tkcYe1paHLH-7eehSzA2 content esgSubNav
In This List

AstraZeneca sells rights to cancer drug for $250M

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


AstraZeneca sells rights to cancer drug for $250M

TerSera Therapeutics LLC acquired the U.S. and Canadian rights to AstraZeneca PLC's cancer drug Zoladex for an up-front payment of $250 million and up to a further $70 million in milestone-related payments and royalties on the drug's sale.

The sale was first announced in February.

Zoladex is an injectable luteinizing hormone-releasing medicine for treating prostate cancer, breast cancer and certain benign gynecological disorders, and was first approved in the U.S. and Canada in 1989.